-161+80pCalb2/dmutNRF-1(-41;-35)-like
(Plasmid
#66741)
-
Purposeluciferase reporter for Calb2 promoter (-161to +80, mutant)
-
Depositing Labs
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 66741 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepGL3 basic
-
Backbone manufacturerPromega
- Backbone size w/o insert (bp) 4818
-
Vector typeMammalian Expression, Luciferase
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameCalb2 promoter (-161bp+80)
-
Alt namecalbindin 2
-
SpeciesH. sapiens (human)
-
Insert Size (bp)241
-
MutationCGCAGGCGC (-41;-35) to ATTAGGATT
-
GenBank ID794
-
Entrez GeneCALB2 (a.k.a. CAB29, CAL2, CR)
- Promoter Calb2
-
Tag
/ Fusion Protein
- luciferase (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site HindIII (not destroyed)
- 3′ cloning site NcoI (not destroyed)
- 5′ sequencing primer REVprimer3
- 3′ sequencing primer GLprimer2 (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
-161+80pCalb2/dmutNRF-1(-41;-35)-like was a gift from Emanuela Felley-Bosco & Rolf Stahel (Addgene plasmid # 66741 ; http://n2t.net/addgene:66741 ; RRID:Addgene_66741) -
For your References section:
Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells. Kresoja-Rakic J, Kapaklikaya E, Ziltener G, Dalcher D, Santoro R, Christensen BC, Johnson KC, Schwaller B, Weder W, Stahel RA, Felley-Bosco E. Oncotarget. 2016 Feb 1. doi: 10.18632/oncotarget.7114. 10.18632/oncotarget.7114 PubMed 26848772